Unlike protein-coding genes, long non-coding RNAs do not serve primarily as templates for producing proteins. Instead, they can regulate gene activity through several mechanisms, including interactions with DNA, chromatin-modifying proteins, transcription factors and messenger RNAs. Some long non-coding RNAs act as molecular scaffolds, bringing regulatory proteins into proximity; others influence the stability or translation of messenger RNAs. LINC02709 appears, according to the study’s title and reported conclusions, to function as a regulator of malignant behavior rather than as a conventional structural component of the cell. Its significance lies in how a non-coding transcript can reshape the phenotype of hepatocellular carcinoma cells and alter their relationship with immune cells in the surrounding liver.

The first process highlighted by the researchers is the expansion of stem cell-like characteristics within tumor cells. In cancer biology, “stemness” does not necessarily mean that a cell is a normal stem cell. It refers to a set of properties that may include the ability to self-renew, survive under stress, generate diverse tumor-cell populations and initiate new tumors more efficiently. These traits can make cancer cells resistant to treatment and better equipped to seed metastases. Tumor plasticity is particularly important in hepatocellular carcinoma because malignant cells can shift between different functional states in response to oxygen deprivation, nutrient limitation, inflammation or therapy. By increasing stem cell-like properties, LINC02709 may help a subset of liver cancer cells remain adaptable while moving through the metastatic cascade.

Metastasis is not a single event but a chain of biological challenges. Cancer cells must detach from the primary tumor, invade nearby tissue, enter blood or lymphatic vessels, survive circulation, exit at a distant organ and adapt to a new microenvironment. Most disseminated cells fail at one or more of these stages. Cells with enhanced stemness may have a greater chance of surviving these obstacles because they can withstand environmental stress and regenerate tumor populations after reaching a new site. The study’s central implication is that LINC02709 may support this process by shifting hepatocellular carcinoma toward a more flexible, resilient and metastasis-capable state. That possibility makes the RNA a candidate marker for aggressive disease and a potential target for future investigation.

The second mechanism involves Kupffer cells, which account for a substantial part of the liver’s innate immune environment. Positioned along the sinusoidal blood vessels, these macrophages continuously sample blood arriving from the gastrointestinal tract and help remove microbes, damaged cells and foreign particles. Their ability to engulf material, a process known as phagocytosis, is one of the liver’s essential defensive functions. In cancer, however, macrophages can be reprogrammed by signals released from tumor cells. They may become less effective at eliminating malignant cells or may adopt states that support tumor growth, tissue remodeling and immune suppression. The reported link between LINC02709 and reduced Kupffer cell phagocytosis suggests that the RNA may help hepatocellular carcinoma evade an important layer of local immune surveillance.

Phagocytosis begins when a macrophage recognizes molecular signals on the surface of a target cell. These signals can include antibodies, complement fragments or “eat-me” markers that distinguish damaged or abnormal cells from healthy tissue. Receptors on the macrophage then trigger cytoskeletal rearrangements, allowing the immune cell to surround and internalize its target. Tumors can interfere with this process by increasing “don’t-eat-me” signals, releasing immunosuppressive factors or altering the metabolism and signaling networks of macrophages. If LINC02709 contributes to this suppression, it could connect a cancer-cell-intrinsic program with a change in the behavior of nearby immune cells. Such a connection would help explain how metastatic tumor cells can avoid removal while simultaneously acquiring properties that favor dissemination.

The study therefore presents LINC02709 as more than a passive molecular signature. It may represent a regulatory node linking tumor plasticity with immune escape. This is important because cancer therapies often focus on one compartment at a time: treatments may directly attack tumor-cell division, while immunotherapies attempt to restore immune recognition. A molecule capable of influencing both the aggressiveness of malignant cells and the activity of Kupffer cells could offer a broader therapeutic entry point. Researchers may now investigate whether blocking LINC02709 reduces stemness, restores macrophage engulfment or limits metastatic growth in experimental models. Such work would also need to determine where the RNA acts inside the cell, which molecules it binds, and whether its effects depend on specific signaling pathways or tumor subtypes.

The findings could eventually have implications for diagnosis and treatment selection, although clinical use would require extensive validation. Measuring LINC02709 in tumor tissue, blood or other biological samples might help identify patients whose cancers have a higher metastatic potential, provided that reliable and specific assays can be developed. Therapeutically, strategies might include antisense oligonucleotides, small interfering RNAs or other approaches designed to reduce the RNA’s activity. However, targeting a long non-coding RNA presents challenges: its expression may vary between tissues, its structure can be difficult to define, and suppressing it must not disrupt essential functions in healthy cells. Restoring Kupffer cell activity would also need to be carefully controlled, since excessive macrophage activation could damage liver tissue or intensify inflammation.

For now, the report places LINC02709 among a growing group of non-coding regulators that are changing how scientists understand liver cancer progression. Hepatocellular carcinoma is shaped not only by mutations that drive uncontrolled growth, but also by reversible changes in cell identity and continuous communication with the immune microenvironment. By describing a relationship between LINC02709, cancer stem cell-like traits and impaired Kupffer cell phagocytosis, the study offers a framework for examining metastasis as both a tumor-cell and ecosystem-level process. The next stage will be to establish the molecular details, test whether the relationship holds across patient populations and determine whether disrupting LINC02709 can prevent spread without harming normal liver defenses. If those questions are answered, a once-overlooked non-coding RNA could become a useful guide to the biology—and potentially the treatment—of metastatic liver cancer.

Subject of Research: LINC02709, hepatocellular carcinoma metastasis, cancer stem cell-like properties and Kupffer cell phagocytosis

Article Title: LINC02709 facilitates hepatocellular carcinoma metastasis by increasing stem cell-like properties and suppressing Kupffer cell phagocytosis.

Article References: Wei, H., Li, W., Wu, X. et al. “LINC02709 facilitates hepatocellular carcinoma metastasis by increasing stem cell-like properties and suppressing Kupffer cell phagocytosis.” Cell Death Discovery (2026). https://doi.org/10.1038/s41420-026-03276-8

Image Credits: AI Generated

DOI: https://doi.org/10.1038/s41420-026-03276-8

Keywords: LINC02709, hepatocellular carcinoma, liver cancer, metastasis, long non-coding RNA, cancer stemness, Kupffer cells, phagocytosis, immune evasion

The researchers found that palmitate supports liver metastasis not only by feeding tumour-cell metabolism, but also by reshaping communication between cancer cells and neutrophils. Neutrophils are best known as rapid-response immune cells that can attack microbes, but they can also kill cancer cells through toxic granules, reactive molecules and other effector mechanisms. In the liver metastatic environment, however, the study indicates that cancer cells can use a palmitate-dependent pathway to make neutrophils less effective.

The central molecular player is DHHC17, a palmitoyltransferase encoded by the gene ZDHHC17. Palmitoyltransferases attach palmitate to proteins, a reversible lipid modification that can alter a protein’s stability, location, interactions or secretion. The study found that breast and colorectal cancer cells that colonize the liver depend on DHHC17 to stabilize laminin-511, a protein complex in the extracellular matrix. Stabilized laminin-511 can then be secreted by the cancer cells into their surroundings.

Laminin-511 is composed of laminin subunits that help organize the tissue environment and influence how cells adhere, migrate and communicate. In the context of liver metastases, its role appears to extend beyond structural support. The investigators observed that neutrophils exposed to laminin-511 reduced their cancer-cell-killing activity. This suggests that the extracellular matrix produced by metastatic cancer cells can function as an immune-regulatory signal, effectively converting a local tissue component into a shield against immune attack.

The relationship was particularly striking in the liver. Cancer cells capable of forming liver metastases required ZDHHC17 for efficient metastatic growth, whereas the same dependency was not observed when the cells spread to the lung. This organ-specific pattern is consistent with the idea that the nutrient environment of a tissue can determine which tumour adaptations are advantageous. The liver’s supply of palmitate may provide the biochemical conditions needed for the DHHC17–laminin-511 pathway to operate efficiently.

To test whether neutrophils were responsible for the metastatic effect, the researchers silenced ZDHHC17 in cancer cells. This reduced liver metastasis formation or growth when neutrophils were present. When neutrophils were absent or their antitumour functions were otherwise limited, the benefit of ZDHHC17 silencing was lost. These findings place neutrophils between the tumour-cell pathway and the reduction in metastatic burden, rather than suggesting that DHHC17 acts only through cancer-cell proliferation.

The experiments also provided a functional rescue of the proposed mechanism. Introducing laminin-511 into metastases formed by ZDHHC17-silenced cancer cells restored metastatic growth. Similarly, blocking neutrophil degranulation, the process by which neutrophils release cytotoxic contents, also reversed the suppressive effect of ZDHHC17 loss. Together, these observations support a model in which palmitate enables cancer cells to produce and secrete laminin-511, laminin-511 dampens neutrophil antitumour behaviour, and weakened neutrophil activity allows liver metastases to expand.

The findings highlight a broader principle in cancer biology: nutrients in the tumour microenvironment can influence disease not only through energy production and biosynthesis, but also through immune regulation. Palmitate is a saturated fatty acid involved in membrane formation, protein modification and cellular signalling. By linking palmitate availability to extracellular-matrix production and neutrophil suppression, the study connects metabolism, tumour architecture and immune escape in a single metastatic pathway.

The work remains preclinical, and several questions will need to be answered before the mechanism can be translated into therapy. It is not yet clear how palmitate levels vary among human liver metastases, whether DHHC17 activity can be safely inhibited, or how blocking laminin-511 would affect normal liver architecture and wound repair. Neutrophils can also have both protective and tumour-promoting roles, meaning that broadly suppressing their activity could produce unwanted consequences. Nevertheless, targeting the DHHC17–laminin-511 axis, altering tumour lipid handling or restoring neutrophil degranulation could eventually offer new strategies against liver metastases from breast, colorectal and possibly other cancers.

Subject of Research: Palmitate-driven immune evasion in liver metastases, involving DHHC17, laminin-511 and neutrophil antitumour activity.

Article Title: Palmitate promotes liver metastases by decreasing neutrophil antitumour behaviour

Article References: Vandekeere, A., Fernández-García, J., Peng-Winkler, Y. et al. “Palmitate promotes liver metastases by decreasing neutrophil antitumour behaviour.” Nature Metabolism (2026). https://doi.org/10.1038/s42255-026-01582-0

Image Credits: AI Generated

DOI: https://doi.org/10.1038/s42255-026-01582-0

Keywords: Liver metastases, palmitate, DHHC17, ZDHHC17, laminin-511, neutrophils, immune evasion, cancer metabolism, breast cancer, colorectal cancer